Jefferies Cautions Against Shorting the Axsome Therapeutics (AXSM) Launch, Reiterates Buy
Tweet Send to a Friend
Jefferies analyst Chris Howerton reiterated a Buy rating and $129.00 price target on Axsome Therapeutics (NASDAQ: AXSM) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
